Your browser doesn't support javascript.
loading
An Investigation of Levetiracetam in Alzheimer's Disease (ILiAD): a double-blind, placebo-controlled, randomised crossover proof of concept study.
Sen, Arjune; Akinola, Mary; Tai, Xin You; Symmonds, Mkael; Davis Jones, Gabriel; Mura, Sergio; Galloway, Joanne; Hallam, Angela; Chan, Jane Y C; Koychev, Ivan; Butler, Chris; Geddes, John; Van Der Putt, Rohan; Thompson, Sian; Manohar, Sanjay G; Frangou, Eleni; Love, Sharon; McShane, Rupert; Husain, Masud.
Afiliação
  • Sen A; Oxford Epilepsy Research Group, NIHR Biomedical Research Centre, John Radcliffe Hospital, Oxford, UK. arjune.sen@ndcn.ox.ac.uk.
  • Akinola M; Department of Neurology, John Radcliffe Hospital, Oxford, OX3 9DU, UK. arjune.sen@ndcn.ox.ac.uk.
  • Tai XY; Nuffield Department of Clinical Neuroscience, University of Oxford, Oxford, OX3 9DU, UK. arjune.sen@ndcn.ox.ac.uk.
  • Symmonds M; Local Clinical Trials Network, John Radcliffe Hospital, Oxford, OX3 9DU, UK.
  • Davis Jones G; Oxford Epilepsy Research Group, NIHR Biomedical Research Centre, John Radcliffe Hospital, Oxford, UK.
  • Mura S; Department of Neurology, John Radcliffe Hospital, Oxford, OX3 9DU, UK.
  • Galloway J; Oxford Epilepsy Research Group, NIHR Biomedical Research Centre, John Radcliffe Hospital, Oxford, UK.
  • Hallam A; Department of Clinical Neurophysiology, John Radcliffe Hospital, Oxford, OX3 9DU, UK.
  • Chan JYC; Oxford Epilepsy Research Group, NIHR Biomedical Research Centre, John Radcliffe Hospital, Oxford, UK.
  • Koychev I; Nuffield Department of Clinical Neuroscience, University of Oxford, Oxford, OX3 9DU, UK.
  • Butler C; Clinical Trials Pharmacy, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK.
  • Geddes J; CPSU, Oxford Health Foundation Trust, Oxford, OX1 5RW, UK.
  • Van Der Putt R; St Mary's Pharmaceutical Unit, Cardiff University, Cardiff, 20 Fieldway, Cardiff, CF14 4HY, UK.
  • Thompson S; Freeline Therapeutics, King's Court, London Road, Stevenage, SG1 2NG, UK.
  • Manohar SG; Translational Medicine, UCB Pharma, 208 Bath Road, Slough, SL1 3WE, UK.
  • Frangou E; Department of Psychiatry, University of Oxford, Oxford, OX3 7JX, UK.
  • Love S; Faculty of Medicine, Department of Brain Sciences, Imperial College, Sir Alexander Fleming Building, South Kensington Campus, London, SW7 2BU, UK.
  • McShane R; Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, OX3 7JX, UK.
  • Husain M; Memory and Cognition Research Delivery Team, Warneford Hospital, Warneford Lane, Headington, Oxford, OX3 7JX, UK.
Trials ; 22(1): 508, 2021 Jul 31.
Article em En | MEDLINE | ID: mdl-34332638
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Alzheimer Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Alzheimer Idioma: En Ano de publicação: 2021 Tipo de documento: Article